A double-blind dose-response study comparing rapid acting intramuscular olanzapine and intramuscular placebo in agitated patients with schizophrenia
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2008
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 03 Sep 2008 Results were presented at ECNP 2008.
- 07 Jun 2007 Status change from recruiting to completed.
- 23 Nov 2006 New trial record.